Balancing Scientific Pursuit and Commercial Revenue: How Medical Innovators Navigate the Tightrope
How long does it take for a new drug or a domestically produced CT scanner to reach consumers?
From early-stage R&D in the laboratory, to productization research, to Phase III clinical trials, and finally to a series of preparations prior to product launch,The High R&D Costs of Commercializing Medical Research Achievements Often Deter Countless Entrepreneurs.
Can the R&D cycle be shortened to accelerate entry into the revenue-generating phase? When will revenue generation begin? Amidst a high cash burn rate, any issue arising at any stage of the R&D process could result in the product’s failure before launch.
So, what level of research precision is sufficient? Can the R&D precision achieved at the cost of time and money truly lead to a competitive advantage against rivals’ first-mover moves?
Therefore,The translation of research findings into clinical applications has long been considered a “valley of death” in the investment community within the medical field.
High risk, high investment, high requirements, long cycle.On the Entrepreneurial Journey in the Healthcare Sector,"Three Highs and One Long"These four major obstacles have forced too many startups to fold, while also deterring numerous investors and scientists harboring research achievements from taking the leap into entrepreneurship.
Scientific research and commercial operations inherently follow distinct underlying logics: the former prioritizes rigor and precision, while the latter emphasizes rapid results.The Clash of Ideologies: A Sharp Contradiction in the Commercialization of Scientific Achievements—How Can Sci-Tech Innovation Teams Find Balance Between Rigorous Precision and Commercialization?
R&D or Revenue: Which Takes Precedence? The Ability to Answer This Question Determines the Survival of Most Healthcare Companies.
This contradiction persists across every facet of corporate operations: How much should be invested in R&D, at what stage should investment occur, and how can a balance between input and output be achieved? These are critical considerations for healthcare companies pursuing technological innovation.
Focusing on the R&D and revenue challenges throughout the entire process of scientific and technological innovation commercialization, VCBeat Chengguo Bureau has organized an online panel discussion titled “R&D and Revenue,” specially invitingMa Dong, Researcher/Ph.D. Supervisor at the Department of Biomedical Engineering, Jinan University; Wang Yingqi, CEO of Topview Medical; Li Ning, Executive Director at Gaorong CapitalExploring and addressing the topic from multiple dimensions—“Why,” “How,” and “What”—we discuss how companies can make trade-offs and achieve balance between R&D and revenue; the prioritization and strategies for pipeline setup in productization research; and new technologies that enhance R&D efficiency amidst the tide of the times.
VCBeat Orange Bureau looks forward to the collision of perspectives from different angles, providing scientists and investors with insights for reference.
